Drug or treatment

Ocrelizumab clinical trials

• 15Clinical trials
• 31Countries

Newest trials

All recruiting trials (15)

• People with Relapsing-Remitting MS try subcutaneous ocrelizumab at their clinic

  This study looks at how satisfied people with relapsing-remitting MS feel about receiving subcutaneous ocrelizumab in routine care.

  Recruiting at 2 sites Hoffmann-La Roche · Pardubice, Pardubice Region and 1 other locations · NCT07827586

• Comparing Ofatumumab vs Ocrelizumab in Real-World MS Care

  This real-world study tests whether ofatumumab works differently from ocrelizumab for people with multiple sclerosis.

  Recruiting Novartis · East Hanover, New Jersey · NCT07779460

• Ocrelizumab given under the skin after switching from another anti-CD20 therapy

  This study tests a subcutaneous form of ocrelizumab mixed with rHuPH20 in people with relapsing or primary progressive MS who are switching from another anti-CD20 treatment.

  Recruiting at 8 sites Phase 4 Genentech, Inc. · Birmingham, Alabama and 7 other locations · NCT07609719

• Switching to ublituximab for ocrelizumab wearing-off in multiple sclerosis

  This pilot will try switching people with relapsing MS who experience symptom 'wearing off' on ocrelizumab to ublituximab to see if their symptoms improve or return later.

  Recruiting Phase 4 Johns Hopkins University · Baltimore, Maryland · NCT07389590

• Adding RO7268489 to ocrelizumab for progressive multiple sclerosis

  This trial will test whether adding RO7268489 to ocrelizumab helps adults with progressive multiple sclerosis.

  Recruiting at 114 sites Phase 2 Hoffmann-La Roche · Camperdown, New South Wales and 113 other locations · NCT07282574

• Ocrelizumab and GLP‑1 agonists in people with multiple sclerosis

  This project will see if taking GLP‑1 weight‑loss medicines while on ocrelizumab changes progression of disability in adults with multiple sclerosis.

  Recruiting Northwestern University · Chicago, Illinois · NCT07207148

• Remibrutinib after switching from ocrelizumab for relapsing multiple sclerosis

  This study will see if remibrutinib, a daily oral BTK inhibitor, keeps relapsing MS under control in people switching from ocrelizumab compared with continuing ocrelizumab.

  Recruiting at 128 sites Phase 3 Novartis · Scottsdale, Arizona and 130 other locations · NCT06846281

• Investigating the effects of ocrelizumab on neurofilament levels and patient satisfaction in multiple sclerosis

  This study is testing how the medication ocrelizumab affects certain markers in the blood and how satisfied people with multiple sclerosis feel about their treatment after a year.

  Recruiting at 86 sites Hoffmann-La Roche · Aachen and 92 other locations · NCT06780150

• Assessing the impact of Multiple Sclerosis on physical function while providing continued ocrelizumab treatment

  This study is testing how Multiple Sclerosis affects physical function while continuing treatment with the medication ocrelizumab for people who have already been part of related studies.

  Recruiting at 53 sites Phase 3 Hoffmann-La Roche · Pleven and 55 other locations · NCT06675955

• Examining personalized treatment for multiple sclerosis with rituximab and ocrelizumab

  This study is testing whether measuring the levels of two different medications, rituximab and ocrelizumab, can help doctors personalize treatment for people with relapsing-remitting multiple sclerosis who are just starting therapy.

  Recruiting Haukeland University Hospital · Bergen, Vestland · NCT06663111

• Comparing Rituximab and Ocrelizumab for Treating Relapsing Multiple Sclerosis

  This study is testing if rituximab works just as well as ocrelizumab for treating relapsing multiple sclerosis in adults.

  Recruiting Phase 3 Amsterdam UMC, location VUmc · Amsterdam · NCT05834855

• Comparing Rituximab and Ocrelizumab for Relapsing-Remitting Multiple Sclerosis

  This study is testing whether rituximab can work just as well as ocrelizumab in helping people with relapsing-remitting multiple sclerosis manage their symptoms over two years.

  Recruiting at 9 sites Phase 3 Rennes University Hospital · Lyon, Bron and 22 other locations · NCT05758831

• Home infusions of ocrelizumab for multiple sclerosis patients

  This study tests whether giving ocrelizumab infusions at home is safe and effective for people with multiple sclerosis.

  Recruiting Phase 4 University of Colorado, Denver · Centennial, Colorado · NCT04650321

• Examining the effects of ocrelizumab in African American and Caucasian patients with relapsing multiple sclerosis

  This study is testing how well ocrelizumab works for treating relapsing multiple sclerosis in African American and Caucasian patients to see if there are any differences in how the disease progresses.

  Recruiting Wayne State University · Detroit, Michigan · NCT04458688

• Using Ocrelizumab to treat psychosis caused by autoimmunity

  This study tests if the medication Ocrelizumab can help young adults with schizo-affective psychosis and schizophrenia caused by autoimmune issues feel better.

  Recruiting Phase 1/2 The Methodist Hospital Research Institute · Houston, Texas · NCT03971487

Quick answers

How many clinical trials of Ocrelizumab are recruiting right now?

15, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 31 countries. The most sites are in United States (8 trials), France (4 trials), Germany (4 trials), Czechia (2 trials), Australia (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 4, Phase 4: 3, Phase 2: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →